성인 기관지확장증 약물치료의 최신지견open accessUpdate on pharmacotherapy for adult bronchiectasis
- Other Titles
- Update on pharmacotherapy for adult bronchiectasis
- Authors
- Choi, Hayoung; Lee, Hyun; Ra, Seung Won; Oh, Yeon-Mok
- Issue Date
- Aug-2020
- Publisher
- KOREAN MEDICAL ASSOC
- Keywords
- Bronchiectasis; Pharmacotherapy; Therapeutics
- Citation
- JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, v.63, no.8, pp.486 - 492
- Indexed
- SCOPUS
KCI
- Journal Title
- JOURNAL OF THE KOREAN MEDICAL ASSOCIATION
- Volume
- 63
- Number
- 8
- Start Page
- 486
- End Page
- 492
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/9050
- DOI
- 10.5124/jkma.2020.63.8.486
- ISSN
- 1975-8456
- Abstract
- Bronchiectasis refers to abnormal dilatation of the bronchi, which leads to the failure of mucus clearance and increased risk of infection. Pharmacotherapy for stable bronchiectasis includes oral or inhaled mucoactive agents, anti-inflammatory therapy, inhaled bronchodilators, long-term antibiotics, and long-term macrolide treatment. Among them, mucoactive agents are the most common adjunctive agents to airway clearance techniques. When patients with impaired lung function suffer from dyspnea, inhaled bronchodilators may be prescribed to relieve the symptom. Long-term macrolide treatment has been proven to prevent exacerbation in patients with frequent bronchiectasis exacerbation. If exacerbation occurs despite the above mentioned treatments, one or two weeks of antibiotics should be prescribed to cover respiratory bacteria that include Pseudomonas aeruginosa. Because evidence supporting the use of pharmacotherapy for bronchiectasis is weak, further research is warranted.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/9050)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.